Sotiburafusp alfa is a humanized bispecific protein that inhibits angiogenesis by targeting VEGFR-1 and blocks the PD-1/PD-L1 immune checkpoint. This engineered fusion protein is utilized in preclinical cancer research to investigate dual mechanisms of tumor growth suppression in both in vitro and in vivo experimental models.